About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.

By: via Business Wire

Access to Premier’s healthcare group purchasing organization (GPO) expected to expand national market reach for Surmodics endovascular thrombectomy solutions.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems.

“This is an exciting development for Surmodics,” said Gary Maharaj, President and Chief Executive Officer of Surmodics. “Our Pounce Arterial and Venous Thrombectomy Systems offer physicians simplicity and procedural efficiency to remove arterial and venous clot without the need for capital equipment. We are confident that our portfolio of thrombectomy systems will contribute meaningfully to high-quality, cost-effective care throughout the Premier hospital alliance.”

The Surmodics thrombectomy portfolio comprises fully mechanical, non-aspiration endovascular systems designed to promptly remove soft or hardened blood clots from peripheral arteries (Pounce Thrombectomy and Pounce Low-Profile [LP] Thrombectomy Systems) or peripheral veins (Pounce Venous Thrombectomy System). Surmodics thrombectomy systems, which do not require capital equipment, are designed to minimize the need for physicians to remove clots using thrombolytic drugs, a treatment that typically requires overnight admission to an intensive care unit.

Premier is a leading healthcare improvement company, uniting an alliance of more than 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About Surmodics, Inc.

Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission.

About Surmodics thrombectomy products

Surmodics’ Pounce Thrombectomy platform devices are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. The Pounce LP Thrombectomy System is indicated for use in vessels ranging from 2 mm to 4 mm in diameter, sizes typical of vessels found below the knee. The Pounce LP System complements the original Pounce Thrombectomy System, introduced in 2021, which is indicated for use in vessels 3.5 mm to 6 mm in diameter.

The Pounce Venous System is indicated for mechanical de-clotting and controlled and selective infusion of physician-specified fluids, including thrombolytics, in the peripheral vasculature. The Pounce Venous System is indicated for use in vessels 6 mm to 16 mm in diameter. The Pounce Venous Systems may be used with the Pounce Sheath (12 Fr), which is intended to introduce therapeutic or diagnostic devices into the vasculature.

For more information on Pounce thrombectomy products, visit www.pouncesystem.com and www.pouncevenous.com.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements regarding the expectation that access to Premier GPO members will expand the national market reach for Surmodics endovascular thrombectomy solutions, the expectation that Surmodics' portfolio of thrombectomy devices will contribute meaningfully to high-quality, cost-effective care throughout the Premier hospital alliance,, and Surmodics’ growth strategy, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the willingness of Premier members to adopt use of the Surmodics thrombectomy products, and the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Contacts

More News

View More
Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
Via MarketBeat
Topics Artificial Intelligence Electric Vehicles
Tickers TSLA
Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
Via MarketBeat
Topics Artificial Intelligence ETFs
Tickers AMZN BABA BIDU GOOGL MCHI
This ETF Weeds Out Small-Cap Underperformers
Via MarketBeat
Topics ETFs Government
Tickers BWA COOP IJR IWM KTOS SNDK
3 Top-Rated Dividend Growth Stocks to Buy in October
Via MarketBeat
Topics Bonds
Tickers PCH PR SFD
2 AI Stocks With Record Breaking Rallies: Can They Continue?
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers AMZN HUT MSFT NBIS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.